James W. Thomas

ORCID: 0000-0002-2098-6458 · 15 papers in corpus · active 2016-2025

Study types

  • article 13
  • rct 2

Condition tags

  • endometriosis 15
  • dysmenorrhea 4
  • mesh:D004715 3
  • mesh:D004412 3
  • mesh:D017699 3
  • mesh:D004414 2
  • dyspareunia 2
article 2025
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain
AJOG global reports ·doi:10.1016/j.xagr.2025.100584

Background: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…

rct 2024
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

article 2024
LONG-TERM ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS + 12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY
·doi:10.1016/j.fertnstert.2024.07.557
article 2023
10173 Long-Term Therapy of Elagolix + Add-Back Therapy in Women with Endometriosis-Associated Pain for 48 Months: Update on Bone Mineral Density
·doi:10.1016/j.jmig.2023.08.336
article 2023
LONG-TERM THERAPY OF ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY
·doi:10.1016/j.fertnstert.2023.08.206
article 2018
Elagolix Reduces Fatigue in Patients With Moderate-to-Severe Endometriosis Pain [34G]
·doi:10.1097/01.aog.0000533384.19860.fd

INTRODUCTION: Endometriosis-associated symptoms like menstrual and non-menstrual pelvic pain can be associated with fatigue. This study evaluated the impact of elagolix, an oral gonadotrophin-releasing hormone antagonist, on fatigue among e…

article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2017
Long-term effect of elagolix on the endometrium: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.147
article 2017
Long-Term Effect of Elagolix on the Endometrium: Results from Two Phase 3 Extension Studies in Women with Endometriosis-Associated Pain
·doi:10.1016/j.jmig.2017.08.051
article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2016
Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.780
article 2016
The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2016.07.274
article 2016
The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire
·doi:10.1016/j.fertnstert.2016.07.271
article 2016
Use of elagolix for the management of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.774